Press release
Atopic Dermatitis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceutical
Atopic Dermatitis Pipeline Analysis
Qurient Co, Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd., GI Innovation, AnaptysBio, MC2 therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology
According to DelveInsight, over 100 leading companies are actively involved in developing more than 110 treatment therapies for Atopic Dermatitis, reflecting a dynamic and expanding pipeline.
Atopic Dermatitis Overview:
Atopic dermatitis (AD), also called eczema, is a long-lasting inflammatory skin disorder that often appears in early childhood but can arise at any age. It manifests as itchy, red, and inflamed patches, with triggers that include genetic predisposition, an overactive immune response, infections, allergens, or irritants. Many individuals with moderate-to-severe AD also suffer from asthma, hay fever, or food allergies, making it the most common chronic skin disease in children.
The development of AD is driven by a complex interplay of factors: impaired skin barrier function, immune system imbalances, and environmental stresses. Mutations in the filaggrin gene worsen the condition by increasing water loss, altering skin pH, and causing dehydration, which weakens the barrier. A skewed balance between Th2 and Th1 cytokines contributes to immune dysregulation and heightened allergic responses. Additionally, spongiosis allows inflammatory signals to accumulate in the skin, and various dendritic cell populations-such as Langerhans cells and inflammatory dendritic epidermal cells-play key roles in driving the disease process.
Request for a detailed insights report on Atopic Dermatitis pipeline insights @ https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Atopic Dermatitis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Atopic Dermatitis Therapeutics Market.
Key Takeaways from the Atopic Dermatitis Pipeline Report
*
DelveInsight's Atopic Dermatitis pipeline report depicts a robust space with 100+ active players working to develop 110+ pipeline therapies for Atopic Dermatitis treatment.
*
In January 2025, Gilead Sciences partnered with Denmark's LEO Pharma to develop treatments for inflammatory diseases, including atopic dermatitis. The collaboration involves Gilead gaining global rights to develop, manufacture, and commercialize the oral STAT6 program, which has shown potential in treating conditions like AD.
*
December 2024 saw the FDA approval of Galderma's nemolizumab for moderate-to-severe atopic dermatitis in patients aged 12 and older who have not adequately responded to topical therapies. Nemolizumab is a subcutaneous monoclonal antibody targeting the interleukin-31 (IL-31) receptor, addressing itch and inflammation associated with AD.
*
In December 2024, the FDA approved Vtama cream for atopic dermatitis in adults and children aged 2 years and older. This nonsteroidal topical treatment demonstrated significant reductions in itch and improved skin clearance in phase 3 trials.
*
In September 2024, Organon announced an agreement to acquire Dermavant, aiming to expand its presence in the skin disorder treatment market. Dermavant's Vtama cream, approved by the FDA in 2022 for psoriasis, was also under FDA review for treating atopic dermatitis, with a decision expected by the end of 2024.
*
In September 2024, the FDA approved Eli Lilly's injectable therapy, Ebglyss, for patients aged 12 and older with moderate-to-severe eczema unresponsive to other treatments. Ebglyss offers a once-monthly dosing regimen, targeting and neutralizing the IL-13 protein implicated in eczema progression.
*
Key Atopic Dermatitis companies such as Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma, Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co, Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd., GI Innovation, AnaptysBio, MC2 therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology, and others are evaluating new drugs for Atopic Dermatitis to improve the treatment landscape.
*
Promising Atopic Dermatitis pipeline therapies in various stages of development include Tapinarof, Etrasimod, B244, Lirentelimab, QY201, and others.
Atopic Dermatitis Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Atopic Dermatitis Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atopic Dermatitis treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Atopic Dermatitis market.
Download our free sample page report on Atopic Dermatitis pipeline insights [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Atopic Dermatitis Emerging Drugs
*
Tapinarof: Dermavant Sciences
*
Etrasimod: Pfizer
*
B244: AOBiome
*
Lirentelimab: Allakos Inc.
*
QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Atopic Dermatitis Companies
More than 100 prominent companies are actively developing treatments for Atopic Dermatitis (AD). Among these, Dermavant Sciences has the most advanced drug candidate, currently in Phase III clinical trials.
DelveInsight's report covers around 110+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Atopic Dermatitis Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Atopic Dermatitis Therapies and Key Companies: Atopic Dermatitis Clinical Trials and advancements [https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Atopic Dermatitis Pipeline Therapeutic Assessment
- Atopic Dermatitis Assessment by Product Type
- Atopic Dermatitis By Stage
- Atopic Dermatitis Assessment by Route of Administration
- Atopic Dermatitis Assessment by Molecule Type
Download Atopic Dermatitis Sample report to know in detail about the Atopic Dermatitis treatment market @ Atopic Dermatitis Therapeutic Assessment [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Atopic Dermatitis Current Treatment Patterns
4. Atopic Dermatitis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Atopic Dermatitis Late-Stage Products (Phase-III)
7. Atopic Dermatitis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Atopic Dermatitis Discontinued Products
13. Atopic Dermatitis Product Profiles
14. Atopic Dermatitis Key Companies
15. Atopic Dermatitis Key Products
16. Dormant and Discontinued Products
17. Atopic Dermatitis Unmet Needs
18. Atopic Dermatitis Future Perspectives
19. Atopic Dermatitis Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Atopic Dermatitis Pipeline Reports Offerings [https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=atopic-dermatitis-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-dermavant-sciences-pfizer-aobiome-allakos-inc-enitiate-biopharmaceutical]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Atopic Dermatitis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceutical here
News-ID: 4132312 • Views: …
More Releases from ABNewswire
Luxenberg Garbett Kelly & George P.C. Provides Guidance on Navigating Workers' C …
New Castle, Pennsylvania - Luxenberg Garbett Kelly & George P.C. (https://www.lgkg.com/navigating-workers-compensation-in-pennsylvania-rights-benefits-and-responsibilities/), a trusted law firm serving injured workers throughout Western Pennsylvania, is providing critical guidance on understanding workers' compensation rights, benefits, and responsibilities under Pennsylvania law. The firm's comprehensive overview emphasizes the importance of knowing how the system functions, including coverage eligibility, benefit types, and the legal processes involved in filing and managing claims. Through the counsel of an experienced…
AC Repair in North Chesterfield, VA - Midlothian Mechanical Expands Fast-Respons …
North Chesterfield, VA - Midlothian Mechanical, a trusted HVAC contractor in North Chesterfield, VA [https://midlomechanical.com/hvac-contractor-north-chesterfield-va], announces expanded fast-response cooling services to meet rising demand for reliable AC repair during peak temperature months. With more homeowners seeking immediate air conditioning support, the company is increasing service capacity, technician availability, and repair responsiveness to deliver faster cooling relief across Chesterfield County.
Professional AC Repair Services in North Chesterfield, VA
Midlothian Mechanical now offers enhanced…
U.S. Pen Testing Companies, Including IBN Technologies, Strengthen Cybersecurity …
U.S. pen testing companies, including IBN Technologies, are driving real-time cybersecurity solutions as threats rise. Organizations face growing risks from sophisticated cyber-attacks, limited internal expertise, and regulatory pressures. By leveraging advanced tools, AI-driven monitoring, and continuous assessments, these companies help businesses minimize vulnerabilities, ensure compliance, and maintain operational resilience.
Pen-testing companies are experiencing rapid growth as organizations face increasingly sophisticated cyber threats and tighter security requirements. As digital systems expand and…
New Analysis Reveals the 50 Jobs Most Exposed to AI Automation - Some Face Over …
Dsmart's AI Automation Risk Report analyzes 784 occupations to identify the 50 jobs most vulnerable to AI automation. Administrative, clerical, and data-processing roles face the highest exposure, ranging from 77.67% to 96.25%. Telemarketers top the list at 96.25%. The report includes expert insights, an interactive tool, and guidance to help workers and policymakers prepare for rapid AI-driven disruption.
HERRIMAN, Utah - A new analysis from EDsmart finds that a concentrated cluster…
More Releases for Atopic
Rising Prevalence Of Atopic Dermatitis Is A Key Catalyst For The Growth Of The A …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Atopic Dermatitis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The scope of the atopic dermatitis market has experienced substantial expansion recently, projected to increase from $8.61 billion in 2024 to reach $9.88 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 14.7%;…
Atopic Dermatitis Market Trends That Will Shape the Next Decade: Insights from P …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
How Large Will the Atopic Dermatitis Market Size By 2025?
The market size for atopic dermatitis has seen significant expansion in the past few years. This expansion is anticipated to continue, with the market size increasing from $8.61 billion in 2024 to $9.96 billion in 2025, exhibiting a compound annual growth rate (CAGR) of…
Atopic Dermatitis Pipeline Outlook Report 2024
DelveInsight's, "Atopic Dermatitis Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including Atopic Dermatitis clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Atopic Dermatitis Pipeline…
Advanced Therapy Revolutionizes Atopic Dermatitis Market Prospects
The atopic dermatitis market size is expected to be valued at USD 15.42 Billion in 2024 and reach USD 30.5 Billion by 2029, growing at a CAGR of 14.5 % from 2024 to 2029.
Atopic dermatitis, known as eczema, is a prevalent skin condition marked by red, inflamed, and itchy skin. It is a chronic condition commonly seen in children but can also impact adults. Atopic dermatitis is thought to result…
Atopic Dermatitis - Drug Pipeline Landscape, 2023
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may crak and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness. Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger…
Atopic Dermatitis - Drug Pipeline Landscape, 2022
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may cr*ck and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness.
Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger an…
